Fig. 4
From: Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
In vitro siponimod application to activated BV2 microglial cell reduces IL-6 and RANTES release. BV2 cells were pre-treated with siponimod prior to stimulation with TNF. The levels of secreted IL-6 (a) and RANTES (b) were measured by Luminex assay on collected media. Application of siponimod to non-activated cells does not modulate the secretion of both molecules. Data were expressed as picograms per milliliter (pg/ml) and were analyzed by one-way ANOVA, followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001